SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001213900-21-044544
Filing Date
2021-08-24
Accepted
2021-08-24 13:25:44
Documents
44
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 REPORT OF FOREIGN PRIVATE ISSUER ea146254-6k_xtlbiopharma.htm   iXBRL 6-K 21059
2 OPERATING AND FINANCIAL REVIEW AND PROSPECTS AS OF JUNE 30, 2021 ea146254ex99-1_xtlbiopharma.htm EX-99.1 59795
3 UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 202 ea146254ex99-2_xtlbiopharma.htm   iXBRL EX-99.2 303427
  Complete submission text file 0001213900-21-044544.txt   1909456

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE xtlb-20210630.xsd EX-101.SCH 39333
5 XBRL CALCULATION FILE xtlb-20210630_cal.xml EX-101.CAL 21780
6 XBRL DEFINITION FILE xtlb-20210630_def.xml EX-101.DEF 97946
7 XBRL LABEL FILE xtlb-20210630_lab.xml EX-101.LAB 200463
8 XBRL PRESENTATION FILE xtlb-20210630_pre.xml EX-101.PRE 103492
9 EXTRACTED XBRL INSTANCE DOCUMENT ea146254-6k_xtlbiopharma_htm.xml XML 216225
Mailing Address 5 HACHAROSHET ST. RAANANA L3 4365603
Business Address XTL BIOPHARMACEUTICALS LTD C/O ALSTON & BIRD LLP, 90 PARK AVENUE NEW YORK NY 10016 972 9 955 7080
XTL BIOPHARMACEUTICALS LTD (Filer) CIK: 0001023549 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3
Type: 6-K | Act: 34 | File No.: 001-36000 | Film No.: 211200949
SIC: 2834 Pharmaceutical Preparations